Healthcare & Pharmaceutical Market Research in Qatar

BioNixus is a pharmaceutical market research firm in Doha and Qatar, designing and executing primary studies for healthcare and pharma teams launching products under the Ministry of Public Health (MoPH) regulatory framework. Our healthcare market research agency covers HCP insight, KOL mapping, patient journey studies, and payer access research — purpose-built for Qatar's public (Hamad Medical Corporation-led) and private healthcare system.

Looking for the full landscape of research providers? Best healthcare market research companies in Qatar compares five specialist and full-service firms by capability.

Best healthcare market research company in Qatar

BioNixus is a leading healthcare market research company in Qatar, specialising in HCP surveys, KOL mapping, and market access research compliant with Ministry of Public Health (MoPH) requirements.

HCP and Physician SurveysBilingual (English/Arabic) interviews and surveys across physicians, pharmacists, and nurses at Hamad Medical Corporation, Sidra Medicine, and private hospitals in Doha.
KOL Mapping and Influence AnalysisIdentify key opinion leaders and map influence networks by therapy area across Qatar's concentrated specialist community.
Market Access and Pricing ResearchFormulary committee research, HMC procurement analysis, and willingness-to-pay studies across Qatar healthcare channels.

BioNixus delivers primary healthcare market research in Qatar with MoPH-aligned methodologies across public and private health systems.

What we research: therapeutic areas and segments in Qatar

Oncology & hematology

Hamad Medical Corporation (HMC) National Center for Cancer Care and Research, and KOL mapping across specialist networks

Biologics & biosimilars

Biologic market access, biosimilar substitution attitudes, and formulary positioning across HMC and Qatar private hospitals

Precision medicine

Genomics adoption, personalized therapy readiness, and biomarker testing behaviour across Qatar oncology centers

Pharmacovigilance

Post-marketing surveillance design and MoPH pharmacovigilance framework research

Diabetes & metabolic

Type 1 and Type 2 treatment algorithms, GLP-1 adoption, and payer coverage across HMC and private-sector channels

Women's and children's health

Paediatric, obstetric, and neonatal research in partnership with Sidra Medicine's quaternary care and research programs

Rare disease & orphan products

Qatar patient community mapping, specialist access, and compassionate use program research

Medical devices & diagnostics

Device adoption, procurement committee behavior, and health technology assessment research for Qatar hospital tenders

Generic injectables & specialty pharma

Generic substitution attitudes, injectable tender dynamics, and hospital formulary management across HMC and private hospital groups

Research audiences: who we reach in Qatar

HCPs — physicians and specialists

Prescribing oncologists, diabetologists, cardiologists, and primary care physicians across Hamad Medical Corporation, Sidra Medicine, and private hospitals and clinics in Doha.

KOLs — key opinion leaders

Qatar academic and clinical thought leaders in target therapy areas. BioNixus maps influence networks across HMC and Sidra Medicine clinical advisory structures.

Patients and caregivers

Patient journey studies, quality-of-life research, and support program needs assessment — conducted with ethics-appropriate consent and multilingual materials.

Payers and hospital committee members

Formulary committee chairs, insurance medical directors, hospital procurement leads, and MoPH policy advisors who shape real-world access.

Pharmacists

Community and hospital pharmacist attitudes, dispensing behaviour, generic substitution practices, and patient counselling patterns across Qatar retail and institutional pharmacy.

Healthcare research methodology

Every BioNixus Qatar healthcare study begins with a single commercial or access decision — launch sequencing, payer narrative, KOL prioritization, or competitive positioning. Instruments, sample frames, and analysis plans are designed backward from that decision.

We combine quantitative rigor (structured HCP surveys, segmentation, adoption models) with qualitative depth (in-depth interviews, virtual advisory boards, paired physician-payer modules) so leadership sees both the metric and the reason behind it.

Fieldwork follows healthcare research standards: screened and verified respondents, documented consent, de-identified reporting, and bilingual materials reviewed for clinical accuracy before launch. Arabic and English execution is standard across all Qatar programs.

For advisory board and real-world evidence (RWE) programs, BioNixus designs sessions compatible with MoPH regulatory frameworks and Hamad Medical Corporation (HMC) institutional review processes — ensuring findings can support access dossiers and reimbursement submissions.

Regulatory and market access depth: MoPH, HMC, and Sidra Medicine

Qatar's single national regulator — the Ministry of Public Health (MoPH) — oversees pharmaceutical registration, clinical research ethics, and the National Health Strategy 2023–2030. Unlike the UAE's multi-emirate structure, pharmaceutical market research in Qatar does not need to segment by region; instead, the critical distinction is between the public sector, led by Hamad Medical Corporation (HMC), and the growing private sector. BioNixus designs studies that reflect this public/private variation rather than treating Qatar as a single undifferentiated channel.

Qatar has among the highest per-capita healthcare expenditure in the MENA region, with substantial public funding channelled through HMC and the National Primary Health Care Corporation (NPHC) and a growing private sector. Research programs map both the clinical access pathway (MoPH registration, HMC formulary committee timing) and the commercial execution layer (employer-sponsored insurance, private hospital procurement, hospital tender cycles).

HMC's national network of around 14 hospitals concentrates public specialist prescribing, while Sidra Medicine — a quaternary women's and children's research hospital affiliated with Qatar Foundation — anchors paediatric and women's health research. Private hospital groups such as Aster, Al Ahli, and Qatar Medical Centre add a parallel commercial channel. BioNixus KOL maps and HCP studies segment by institution and specialty so you target influence where it actually sits for your therapy area.

Why pharmaceutical teams choose BioNixus in Qatar

✓Specialist in pharma and healthcare research — not a generalist panel company running healthcare as a sideline
✓Verified Qatar physician and specialist panels across Hamad Medical Corporation, Sidra Medicine, and private hospitals
✓Bilingual Arabic–English fieldwork with culturally validated instruments
✓Deep MoPH regulatory context and National Health Strategy 2023–2030 awareness built into study design
✓Dual quantitative and qualitative capability in one team — no subcontracting
✓Real-world evidence and advisory board program design compatible with Qatar access submissions
✓15+ years of healthcare research experience across 38 countries

Related Qatar healthcare research resources

Top pharmaceutical companies in Qatar Qatar pharmaceutical market research Qatar market access research Market research in Qatar (hub)Best market research companies in Qatar Best healthcare market research companies in Qatar

FAQs

What are the best pharmaceutical market research firms in Qatar?

BioNixus is a leading pharmaceutical market research firm in Qatar, delivering HCP, KOL, patient, and payer studies aligned with Ministry of Public Health (MoPH) requirements. We combine primary research depth with Qatar-specific panel access and bilingual fieldwork.

What does a healthcare market research agency in Qatar typically do?

A healthcare market research agency in Qatar designs and executes studies covering physician attitudes, payer access, patient journeys, and competitive landscape for pharmaceutical and medical device companies launching in the country.

How is Qatar different from the UAE for healthcare market research?

Qatar operates under a single national regulator — the Ministry of Public Health (MoPH) — rather than the UAE's multi-emirate structure of DHA, DoH, and MOHAP. In Qatar, the key market distinction is public sector (led by Hamad Medical Corporation) versus private sector, not regional regulatory variation.

What therapeutic areas do pharmaceutical market research companies in Qatar cover?

BioNixus covers oncology, diabetes, cardiology, immunology, rare diseases, biologics, biosimilars, vaccines, medical devices, and diagnostics across the Qatar market, including paediatric and women's health areas relevant to Sidra Medicine.

Can BioNixus recruit HCPs and KOLs in Qatar?

Yes. We maintain physician and specialist panels across Hamad Medical Corporation (HMC), Sidra Medicine, and Qatar's private hospital groups. For scarce specialties like oncology or rare disease, we extend to hospital networks and medical association directories with longer recruitment planning.

What is the typical timeline for healthcare market research in Qatar?

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programs including payer depth and advisory modules typically run 5–8 weeks depending on therapy scarcity and ethics requirements.

Does healthcare market research in Qatar cover precision medicine and biologics?

Yes. BioNixus runs studies covering biologics, biosimilars, precision medicine, pharmacovigilance, and specialty injectables — reflecting Qatar's growing advanced therapy market across HMC and private-sector channels.

What is the size of the Qatar pharmaceutical and healthcare market?

The Qatar pharmaceutical and healthcare market is valued at approximately $1.2 billion and growing at around 6% annually, supported by very high per-capita healthcare spend — among the highest in the MENA region — and sustained investment under Qatar National Vision 2030.

Discuss your Qatar pharmaceutical research strategy

Our team supports pharmaceutical companies with decision-ready insights across the Americas, Europe, and the Middle East using quantitative and qualitative methodologies.

Request a proposal Email us

US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323